TF and breast carcinoma: The combined use of the lysosome disrupting agent siramesine and the tyrosine kinase inhibitor lapatinib can induce the accumulation of intracellular iron ions by reducing the expression of ferroportin (FPN) and increasing the expression of TF, and induces MDA MB 231, MCF-7, ZR -75 and SKBr3 breast cancer cells undergo ferroptosis, which provides a new strategy for the treatment of breast cancer 113.